ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2017
Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Surveillance HeartCare® Outcomes Registry
Pulmonary Hypertension (PH) Biorepository for Translational Research
Who cites it
42 citing papers in PubMed, 68 citations in OpenAlex.
- Donor-Derived Cell-Free DNA at Diagnosis of Cardiac Allograft Rejection Stratifies Risk of Mortality and Graft Dysfunction.Circulation. Heart failure · 2026Article
- Plasma Cell-free DNA Associated With Risk of Mortality and Chronic Lung Allograft Dysfunction Among Lung Transplant Recipients WithTransplantation direct · 2026Article
- Molecular criteria for pulmonary antibody-mediated rejection are associated with an increased risk of allograft failure.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025Observational
- Donor-Derived Cell-Free DNA Stratifies Risk of Mortality and Graft Dysfunction in Severe Acute Cardiac Allograft Rejection.medRxiv : the preprint server for health sciences · 2025Article
- Sustained Molecular Allograft Injury After Episodes of Acute Rejection and Organizing Pneumonia Increases the Risk of Lung Allograft Failure.Transplantation direct · 2025Article
- CELL FREE DNA-BASED PREDICTION OF PROGNOSIS FOR PATIENTS ON VENO-ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION.Shock (Augusta, Ga.) · 2025Article
- Potential of plasma biomarkers for heart failure prediction, management, and prognosis: A multiomics perspective.Heart failure reviews · 2025Review
- %dd-cfDNA: The New Frontier for Heart/Lung Transplant Surveillance?Transplant international : official journal of the European Society for Organ Transplantation · 2025Review
- Circulating biomarkers in pulmonary arterial hypertension: State-of-the-art review and future directions.JHLT open · 2024Review
- Extreme elevations of donor-derived cell-free DNA increases the risk of chronic lung allograft dysfunction and death, even without clinical manifestations of disease.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024Article
- Baseline Lung Allograft Dysfunction After Bilateral Lung Transplantation Is Associated With an Increased Risk of Death: Results From a Multicenter Cohort Study.Transplantation direct · 2024Article
- Higher Molecular Injury at Diagnosis of Acute Cellular Rejection Increases the Risk of Lung Allograft Failure: A Clinical Trial.American journal of respiratory and critical care medicine · 2024Article
- Racial Differences in Donor-Derived Cell-Free DNA and Mitochondrial DNA After Heart Transplantation, on Behalf of the GRAfT Investigators.Circulation. Heart failure · 2024Article
- Organizing pneumonia is associated with molecular allograft injury and the development of antibody-mediated rejection.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024Article
- Cell-Free DNA Maps Tissue Injury and Correlates with Disease Severity in Lung Transplant Candidates.American journal of respiratory and critical care medicine · 2024Article
- Application of graft-derived cell-free DNA for solid organ transplantation.Frontiers in immunology · 2024Review
- Donor-Derived Cell-Free DNA at 1 Month after Kidney Transplantation Relates to HLA Class II Eplet Mismatch Load.Biomedicines · 2023Article
- Cell-free Chromatin Immunoprecipitation to detect molecular pathways in Physiological and Disease States.bioRxiv : the preprint server for biology · 2023Article
- Liquid Biopsy, a Potential New Detection Method in Heart Allograft Rejection.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundUse of new genomic techniques in clinical settings requires that such methods are rigorous and reproducible. Previous studies have shown that quantitation of donor-derived cell-free DNA (%ddcfDNA) by unbiased shotgun sequencing is a sensitive, non-invasive marker of acute rejection after heart transplantation. The primary goal of this study was to assess the reproducibility of %ddcfDNA measurements across technical replicates, manual vs automated platforms, and rejection phenotypes in distinct patient cohorts.
methodsAfter developing and validating the %ddcfDNA assay, we subjected the method to a rigorous test of its reproducibility. We measured %ddcfDNA in technical replicates performed by 2 independent laboratories and verified the reproducibility of %ddcfDNA patterns of 2 rejection phenotypes: acute cellular rejection and antibody-mediated rejection in distinct patient cohorts.
resultsWe observed strong concordance of technical-replicate %ddcfDNA measurements across 2 independent laboratories (slope = 1.02, R
conclusionsThe %ddcfDNA assay is precise and reproducible across laboratories and in samples from 2 distinct types of heart transplant rejection. These findings pave the way for larger studies to assess the clinical utility of %ddcfDNA as a marker of acute rejection after heart transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.